155 related articles for article (PubMed ID: 36673041)
1. Usefulness of Chromogenic Media with Fluconazole Supplementation for Presumptive Identification of
Ruiz-Gaitán A; Sigona-Giangreco I; Pérez-Royo JM; Garcia-Bustos V; García-Hita M; Valentín-Gómez E; Almaraz SG; de Groot PWJ; Pemán J
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673041
[TBL] [Abstract][Full Text] [Related]
2. CHROMagarTM Candida Plus: A novel chromogenic agar that permits the rapid identification of Candida auris.
Borman AM; Fraser M; Johnson EM
Med Mycol; 2021 Mar; 59(3):253-258. PubMed ID: 32525988
[TBL] [Abstract][Full Text] [Related]
3. Novel Chromogenic Medium CHROMagar
Mulet Bayona JV; Salvador García C; Tormo Palop N; Valentín Martín A; González Padrón C; Colomina Rodríguez J; Pemán J; Gimeno Cardona C
J Fungi (Basel); 2022 Mar; 8(3):. PubMed ID: 35330283
[TBL] [Abstract][Full Text] [Related]
4. Performance of Two Novel Chromogenic Media for the Identification of Multidrug-Resistant Candida auris Compared with Other Commercially Available Formulations.
de Jong AW; Dieleman C; Carbia M; Mohd Tap R; Hagen F
J Clin Microbiol; 2021 Mar; 59(4):. PubMed ID: 33536293
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar™ Candida for the detection of Candida auris in surveillance samples.
Mulet Bayona JV; Salvador García C; Tormo Palop N; Gimeno Cardona C
Diagn Microbiol Infect Dis; 2020 Dec; 98(4):115168. PubMed ID: 32927410
[TBL] [Abstract][Full Text] [Related]
6. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species.
Odds FC; Bernaerts R
J Clin Microbiol; 1994 Aug; 32(8):1923-9. PubMed ID: 7989544
[TBL] [Abstract][Full Text] [Related]
7. Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples.
Marathe A; Zhu Y; Chaturvedi V; Chaturvedi S
Mycopathologia; 2022 Dec; 187(5-6):527-534. PubMed ID: 36355325
[TBL] [Abstract][Full Text] [Related]
8. CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures.
Tan GL; Peterson EM
J Clin Microbiol; 2005 Apr; 43(4):1727-31. PubMed ID: 15814992
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CHROMagar™ Candida Plus chromogenic agar for the presumptive identification of Candida auris.
Tamura T; Alshahni MM; Makimura K
Microbiol Immunol; 2022 Jun; 66(6):292-298. PubMed ID: 35229341
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the CHROMagar Candida Plus medium for presumptive identification of yeasts and MALDI-TOF MS identification.
Taverna CG; Vivot ME; Arias BA; Irazu L; Canteros CE
Mycoses; 2023 Nov; 66(11):977-983. PubMed ID: 37518770
[TBL] [Abstract][Full Text] [Related]
11. Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida.
Hospenthal DR; Beckius ML; Floyd KL; Horvath LL; Murray CK
Ann Clin Microbiol Antimicrob; 2006 Jan; 5():1. PubMed ID: 16390552
[TBL] [Abstract][Full Text] [Related]
12. Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal's medium.
Kumar A; Sachu A; Mohan K; Vinod V; Dinesh K; Karim S
Rev Iberoam Micol; 2017; 34(2):109-111. PubMed ID: 28392225
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the first Candida auris isolates reported from Türkiye in terms of identification by various methods and susceptibility to antifungal drugs.
Erkose Genc G; Caklovica Kucukkaya I; Komec S; Toker Onder I; Toptas O; Teke L; Turan D; Aygun G; Gulmez D; Arikan Akdagli S; Erturan Z
Indian J Med Microbiol; 2024; 49():100594. PubMed ID: 38636843
[TBL] [Abstract][Full Text] [Related]
14. Candida auris and some Candida parapsilosis strains exhibit similar characteristics on CHROMagarTMCandida Plus.
Sasoni N; Maidana M; Latorre-Rapela MG; Morales-Lopez S; Berrio I; Gamarra S; Garcia-Effron G
Med Mycol; 2022 Oct; ():. PubMed ID: 36208938
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CHROMagar
Bentz ML; Le N; Min B; Nunnally NS; Sullivan V; Tran M; Lockhart SR; Litvintseva A; Berkow EL; Sexton DJ
Microbiol Spectr; 2024 Apr; 12(4):e0356423. PubMed ID: 38364098
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Mutations in
Rybak JM; Muñoz JF; Barker KS; Parker JE; Esquivel BD; Berkow EL; Lockhart SR; Gade L; Palmer GE; White TC; Kelly SL; Cuomo CA; Rogers PD
mBio; 2020 May; 11(3):. PubMed ID: 32398311
[No Abstract] [Full Text] [Related]
18. APX001A
Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
[TBL] [Abstract][Full Text] [Related]
19. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
Linares MJ; Charriel G; Solís F; Casal M
Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
[TBL] [Abstract][Full Text] [Related]
20. Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait.
Khan Z; Ahmad S; Al-Sweih N; Joseph L; Alfouzan W; Asadzadeh M
PLoS One; 2018; 13(4):e0195743. PubMed ID: 29630658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
